Symbols / ADMA Stock $8.17 -3.54% ADMA Biologics, Inc.

Healthcare • Biotechnology • United States • NGM
ADMA (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Biotechnology
CEO Mr. Adam S. Grossman
Exch · Country NGM · United States
Market Cap 1.89B
Enterprise Value 43.64B
Income 165.35M
Sales 509.86M
FCF (ttm) 58.35M
Book/sh 2.01
Cash/sh 241.28
Employees 640
Insider 10d —
IPO Oct 17, 2013
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E 12.01
Forward P/E 7.73
PEG —
P/S 3.71
P/B 4.07
P/C —
EV/EBITDA 203.15
EV/Sales 85.59
Quick Ratio 3.73
Current Ratio 6.95
Debt/Eq 110.67
LT Debt/Eq —
EPS (ttm) 0.68
EPS next Y 1.06
EPS Growth —
Revenue Growth 15.90%
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2026-08-05
Earnings (prior) 2026-05-06
ROA 21.99%
ROE 43.30%
ROIC —
Gross Margin 61.27%
Oper. Margin -123.39%
Profit Margin 32.43%
Shs Outstand 231.77M
Shs Float 226.77M
Insider Own 1.85%
Instit Own 97.60%
Short Float 10.16%
Short Ratio 2.02
Short Interest 19.31M
52W High 22.37
vs 52W High -63.48%
52W Low 7.21
vs 52W Low 13.31%
Beta 0.82
Impl. Vol. 58.20%
Rel Volume 1.45
Avg Volume 7.03M
Volume 10.17M
Target (mean) $16.75
Tgt Median $17.50
Tgt Low $12.00
Tgt High $20.00
# Analysts 4
Recom Strong_buy
Prev Close $8.47
Price $8.17
Change -3.54%
About

ADMA Biologics, Inc., a biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company operates through ADMA BioManufacturing and Plasma Collection Centers segments. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB, a human polyclonal antibody product for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It also develops a pipeline of plasma-derived therapeutics comprising products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, the company operates source plasma collection facilities. The company sells its products through independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$16.75
Mean price target
2. Current target
$8.17
Latest analyst target
3. DCF / Fair value
$4.53
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$8.17
Low
$12.00
High
$20.00
Mean
$16.75

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-05-07 main Canaccord Genuity Buy → Buy $18
2026-05-07 main Mizuho Outperform → Outperform $20
2026-04-21 init Canaccord Genuity — → Buy $21
2026-04-13 main Mizuho Outperform → Outperform $24
2026-03-26 down Cantor Fitzgerald Overweight → Neutral —
2025-05-08 main Raymond James Strong Buy → Strong Buy $32
2025-03-04 reit Cantor Fitzgerald Overweight → Overweight $25
2024-11-08 main HC Wainwright & Co. Buy → Buy $26
2024-11-08 main Raymond James Strong Buy → Strong Buy $25
2024-10-14 reit HC Wainwright & Co. Buy → Buy $18
2024-09-20 reit Cantor Fitzgerald Overweight → Overweight $20
2024-08-12 main HC Wainwright & Co. Buy → Buy $18
2024-08-09 main Cantor Fitzgerald Overweight → Overweight $20
2024-07-09 main Cantor Fitzgerald Overweight → Overweight $15
2024-06-20 main Mizuho Buy → Buy $14
2024-05-10 main Raymond James Strong Buy → Strong Buy $10
2024-05-10 main Cantor Fitzgerald Overweight → Overweight $10
2024-05-10 main HC Wainwright & Co. Buy → Buy $10
2024-05-10 main Mizuho Buy → Buy $12
2024-03-26 reit HC Wainwright & Co. Buy → Buy $8
News
RSS: Latest ADMA news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2026-03-17 GUIHEEN LAWRENCE P Director — 30,000 $0.00 $0
2026-03-16 GROSSMAN ADAM S Chief Executive Officer — 21,000 $15.16 $318,360
2026-03-16 GROSSMAN ADAM S Chief Executive Officer — 15,000 $5.40 $81,000
2026-03-13 GUIHEEN LAWRENCE P Director — 30,000 $3.66 $109,800
2026-03-09 KESTENBERG-MESSINA KAITLIN M. Officer — 10,096 $15.63 $157,800
2026-03-09 KESTENBERG-MESSINA KAITLIN M. Officer — 10,096 $1.55 $32,331
2026-03-06 ELMS STEVEN A Director — 14,000 $15.39 $217,420
2026-02-17 GROSSMAN ADAM S Chief Executive Officer — 21,000 $16.08 $337,680
2026-02-17 GROSSMAN ADAM S Chief Executive Officer — 15,000 $5.40 $81,000
2026-02-09 KWON YOUNG T. PH.D. Director — 10,690 $0.00 $0
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
510.17
+19.63%
426.45
+65.15%
258.21
+67.59%
154.08
Operating Revenue
510.17
+19.63%
426.45
+65.15%
258.21
+67.59%
154.08
Cost Of Revenue
217.41
+5.08%
206.90
+22.23%
169.27
+42.47%
118.81
Reconciled Cost Of Revenue
209.46
+5.13%
199.24
+23.24%
161.66
+43.81%
112.42
Gross Profit
292.76
+33.35%
219.55
+146.85%
88.94
+152.21%
35.27
Operating Expense
101.32
+25.76%
80.57
+19.70%
67.31
-9.81%
74.63
Research And Development
4.76
+162.66%
1.81
-45.06%
3.30
-8.69%
3.61
Selling General And Administration
91.58
+23.55%
74.12
+25.59%
59.02
+12.51%
52.46
Other Operating Expenses
4.84
+13.92%
4.25
-0.49%
4.27
-76.09%
17.84
Total Expenses
318.73
+10.87%
287.47
+21.51%
236.58
+22.30%
193.44
Operating Income
191.44
+37.75%
138.98
+542.49%
21.63
+154.95%
-39.37
Total Operating Income As Reported
191.44
+37.75%
138.98
+542.49%
21.63
+154.95%
-39.37
EBITDA
197.86
+33.97%
147.69
+2784.55%
5.12
+112.96%
-39.51
Normalized EBITDA
201.20
+35.09%
148.93
+375.91%
31.29
+195.29%
-32.84
Reconciled Depreciation
8.10
+0.63%
8.04
-3.44%
8.33
+17.14%
7.11
EBIT
189.77
+35.89%
139.64
+4447.57%
-3.21
+93.11%
-46.62
Total Unusual Items
-3.34
-168.38%
-1.24
+95.25%
-26.17
-292.41%
-6.67
Total Unusual Items Excluding Goodwill
-3.34
-168.38%
-1.24
+95.25%
-26.17
-292.41%
-6.67
Special Income Charges
-3.34
-168.38%
-1.24
+95.25%
-26.17
-292.41%
-6.67
Other Special Charges
3.34
+168.38%
1.24
-95.25%
26.17
+292.41%
6.67
Net Income
146.93
-25.67%
197.67
+800.00%
-28.24
+57.15%
-65.90
Pretax Income
182.66
+45.29%
125.71
+545.18%
-28.24
+57.15%
-65.90
Net Non Operating Interest Income Expense
-5.24
+55.73%
-11.83
+49.45%
-23.41
-21.71%
-19.23
Interest Expense Non Operating
7.11
-48.96%
13.93
-44.34%
25.03
+29.81%
19.28
Net Interest Income
-5.24
+55.73%
-11.83
+49.45%
-23.41
-21.71%
-19.23
Interest Expense
7.11
-48.96%
13.93
-44.34%
25.03
+29.81%
19.28
Interest Income Non Operating
1.87
-10.78%
2.10
+29.68%
1.62
+3493.33%
0.04
Interest Income
1.87
-10.78%
2.10
+29.68%
1.62
+3493.33%
0.04
Other Income Expense
-3.55
-147.08%
-1.44
+94.57%
-26.46
-262.23%
-7.30
Other Non Operating Income Expenses
-0.21
-9.84%
-0.19
+32.75%
-0.29
+54.80%
-0.64
Tax Provision
35.73
+149.65%
-71.96
0.00
0.00
Tax Rate For Calcs
0.00
-6.67%
0.00
0.00
0.00
Tax Effect Of Unusual Items
-0.65
-150.49%
-0.26
0.00
0.00
Net Income Including Noncontrolling Interests
146.93
-25.67%
197.67
+800.00%
-28.24
+57.15%
-65.90
Net Income From Continuing Operation Net Minority Interest
146.93
-25.67%
197.67
+800.00%
-28.24
+57.15%
-65.90
Net Income From Continuing And Discontinued Operation
146.93
-25.67%
197.67
+800.00%
-28.24
+57.15%
-65.90
Net Income Continuous Operations
146.93
-25.67%
197.67
+800.00%
-28.24
+57.15%
-65.90
Normalized Income
149.61
-24.69%
198.65
+9720.10%
-2.06
+96.51%
-59.23
Net Income Common Stockholders
146.93
-25.67%
197.67
+800.00%
-28.24
+57.15%
-65.90
Diluted EPS
—
0.81
+723.08%
-0.13
+60.61%
-0.33
Basic EPS
—
0.85
+753.85%
-0.13
+60.61%
-0.33
Basic Average Shares
—
233.08
+4.07%
223.98
+13.19%
197.87
Diluted Average Shares
—
243.34
+8.65%
223.98
+13.19%
197.87
Diluted NI Availto Com Stockholders
146.93
-25.67%
197.67
+800.00%
-28.24
+57.15%
-65.90
Amortization
0.14
-62.89%
0.39
-46.41%
0.72
+1.26%
0.71
Amortization Of Intangibles Income Statement
0.14
-62.89%
0.39
-46.41%
0.72
+1.26%
0.71
Depreciation Amortization Depletion Income Statement
0.14
-62.89%
0.39
-46.41%
0.72
+1.26%
0.71
Depreciation And Amortization In Income Statement
0.14
-62.89%
0.39
-46.41%
0.72
+1.26%
0.71
Line Item Trend 2025-12-31
Total Assets
624.24
Current Assets
466.51
Cash Cash Equivalents And Short Term Investments
87.63
Cash And Cash Equivalents
87.63
Receivables
158.43
Accounts Receivable
158.43
Gross Accounts Receivable
158.73
Allowance For Doubtful Accounts Receivable
-0.30
Inventory
206.47
Raw Materials
96.61
Work In Process
57.80
Finished Goods
52.05
Prepaid Assets
—
Assets Held For Sale Current
6.53
Other Current Assets
7.46
Total Non Current Assets
157.73
Net PPE
71.71
Gross PPE
110.06
Accumulated Depreciation
-38.35
Properties
0.00
Land And Improvements
13.04
Buildings And Improvements
26.89
Machinery Furniture Equipment
11.92
Construction In Progress
8.46
Other Properties
34.77
Leases
14.98
Goodwill And Other Intangible Assets
4.16
Goodwill
3.53
Other Intangible Assets
0.63
Non Current Deferred Assets
73.26
Non Current Deferred Taxes Assets
73.26
Non Current Prepaid Assets
—
Other Non Current Assets
8.60
Total Liabilities Net Minority Interest
146.92
Current Liabilities
69.54
Payables And Accrued Expenses
58.82
Payables
31.14
Accounts Payable
22.52
Current Accrued Expenses
27.68
Total Tax Payable
8.62
Income Tax Payable
8.62
Current Debt And Capital Lease Obligation
3.91
Current Debt
2.81
Other Current Borrowings
2.81
Current Capital Lease Obligation
1.10
Current Deferred Liabilities
—
Current Deferred Revenue
—
Other Current Liabilities
6.82
Total Non Current Liabilities Net Minority Interest
77.38
Long Term Debt And Capital Lease Obligation
75.98
Long Term Debt
69.33
Long Term Capital Lease Obligation
6.65
Non Current Deferred Liabilities
1.41
Non Current Deferred Revenue
1.41
Other Non Current Liabilities
—
Stockholders Equity
477.32
Common Stock Equity
477.32
Capital Stock
0.02
Common Stock
0.02
Preferred Stock
0.00
Share Issued
239.79
Ordinary Shares Number
237.87
Treasury Shares Number
1.92
Additional Paid In Capital
671.04
Retained Earnings
-161.65
Treasury Stock
32.09
Total Equity Gross Minority Interest
477.32
Total Capitalization
546.65
Working Capital
396.97
Invested Capital
549.46
Total Debt
79.89
Net Debt
—
Capital Lease Obligations
7.74
Net Tangible Assets
473.16
Tangible Book Value
473.16
Interest Payable
0.17
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
50.40
-57.53%
118.67
+1248.55%
8.80
+114.79%
-59.51
Cash Flow From Continuing Operating Activities
50.40
-57.53%
118.67
+1248.55%
8.80
+114.79%
-59.51
Net Income From Continuing Operations
146.93
-25.67%
197.67
+800.00%
-28.24
+57.15%
-65.90
Depreciation Amortization Depletion
8.10
+0.63%
8.04
-3.44%
8.33
+17.14%
7.11
Depreciation And Amortization
8.10
+0.63%
8.04
-3.44%
8.33
+17.14%
7.11
Other Non Cash Items
0.57
-28.96%
0.81
-87.15%
6.29
+19.59%
5.26
Stock Based Compensation
20.03
+47.08%
13.62
+120.07%
6.19
+18.64%
5.21
Deferred Tax
11.02
+113.08%
-84.28
0.00
0.00
Deferred Income Tax
11.02
+113.08%
-84.28
0.00
0.00
Operating Gains Losses
3.35
+147.96%
1.35
-94.88%
26.36
+271.37%
7.10
Gain Loss On Sale Of PPE
0.01
-91.51%
0.11
-41.76%
0.18
-57.38%
0.43
Change In Working Capital
-139.59
-652.98%
-18.54
-83.14%
-10.12
+44.64%
-18.29
Change In Receivables
-108.43
-380.25%
-22.58
-89.48%
-11.92
-191.16%
13.07
Changes In Account Receivables
-108.43
-380.25%
-22.58
-89.48%
-11.92
-191.16%
13.07
Change In Inventory
-36.23
-1456.42%
2.67
+127.75%
-9.63
+75.03%
-38.56
Change In Prepaid Assets
-1.25
+53.51%
-2.68
-418.67%
0.84
+232.65%
-0.63
Change In Payables And Accrued Expense
7.54
+45.26%
5.19
-54.33%
11.37
+36.42%
8.33
Change In Accrued Expense
5.21
+400.19%
1.04
-86.16%
7.53
-0.05%
7.53
Change In Payable
2.33
-43.86%
4.15
+8.10%
3.84
+379.88%
0.80
Change In Account Payable
2.33
-43.86%
4.15
+8.10%
3.84
+379.88%
0.80
Change In Other Current Liabilities
-1.23
-7.60%
-1.14
-44.63%
-0.79
-57.57%
-0.50
Investing Cash Flow
-21.89
-155.29%
-8.57
-72.15%
-4.98
+64.19%
-13.91
Cash Flow From Continuing Investing Activities
-21.89
-155.29%
-8.57
-72.15%
-4.98
+64.19%
-13.91
Net PPE Purchase And Sale
-22.57
-174.43%
-8.23
-72.42%
-4.77
+65.70%
-13.91
Purchase Of PPE
-22.57
-174.43%
-8.23
-72.42%
-4.77
+65.70%
-13.91
Sale Of PPE
—
—
—
—
Capital Expenditure
-22.89
-166.95%
-8.57
-72.15%
-4.98
+64.19%
-13.91
Net Intangibles Purchase And Sale
-0.32
+9.46%
-0.35
-66.19%
-0.21
0.00
Purchase Of Intangibles
-0.32
+9.46%
-0.35
-66.19%
-0.21
0.00
Net Other Investing Changes
1.00
—
—
—
Financing Cash Flow
-44.02
+24.49%
-58.30
-49.53%
-38.99
-135.82%
108.85
Cash Flow From Continuing Financing Activities
-44.02
+24.49%
-58.30
-49.53%
-38.99
-135.82%
108.85
Net Issuance Payments Of Debt
-0.94
+98.44%
-60.00
-154.23%
-23.60
-145.64%
51.71
Issuance Of Debt
105.00
0.00
-100.00%
135.00
-11.04%
151.75
Repayment Of Debt
-105.94
-76.56%
-60.00
+62.17%
-158.60
-58.54%
-100.04
Long Term Debt Issuance
105.00
0.00
-100.00%
135.00
-11.04%
151.75
Long Term Debt Payments
-105.94
-76.56%
-60.00
+62.17%
-158.60
-58.54%
-100.04
Net Long Term Debt Issuance
-0.94
+98.44%
-60.00
-154.23%
-23.60
-145.64%
51.71
Net Common Stock Issuance
-31.94
0.00
0.00
-100.00%
64.64
Common Stock Payments
-31.94
—
—
—
Repurchase Of Capital Stock
-31.94
—
—
—
Proceeds From Stock Option Exercised
2.98
-60.18%
7.49
+578.80%
1.10
+530.86%
0.17
Net Other Financing Charges
-14.13
-143.75%
-5.80
+64.86%
-16.49
-114.68%
-7.68
Changes In Cash
-15.52
-129.96%
51.80
+247.27%
-35.17
-199.26%
35.43
Beginning Cash Position
103.15
+100.86%
51.35
-40.65%
86.52
+69.36%
51.09
End Cash Position
87.63
-15.04%
103.15
+100.86%
51.35
-40.65%
86.52
Free Cash Flow
27.50
-75.02%
110.10
+2782.88%
3.82
+105.20%
-73.42
Interest Paid Supplemental Data
9.08
-14.90%
10.67
-40.90%
18.05
+30.05%
13.88
Income Tax Paid Supplemental Data
19.68
+109.57%
9.39
0.00
0.00
Common Stock Issuance
—
0.00
0.00
-100.00%
64.64
Issuance Of Capital Stock
—
0.00
0.00
-100.00%
64.64
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category